Revelation Biosciences Presented Data Showing Pretreatment With Gemini, Improved Kidney Function With Reduced Serum Blood Urea Nitrogen And Creatinine, Urine C-reactive Protein, And Acute Kidney Injury-Related Inflammation
Author: Benzinga Newsdesk | March 12, 2024 06:24am
Gemini is the company's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) for systemic administration. It is being developed as a potential therapy for prevention and treatment of hospital acquired infection (REVTx-100 program) and as a potential treatment for acute and chronic organ disease including prevention of acute kidney injury (REVTx-300 program), myocarditis, and chronic kidney disease (CKD).
Posted In: REVB